Clinical trial · Interventional
Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer
Phase II Single-arm Trial of Nab-Paclitaxel and S-1 as Neoadjuvant Treatment of Patients With Resectable Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
There were limited data for nab-paclitaxel and S-1 in pancreatic cancer. To explore the efficacy and safety of neoadjuvant nab-paclitaxel combined with S-1 in patients with resectable pancreatic cancer (stage II and partial stage III defined according to the National Comprehensive Cancer Network definitions ), we designed this study. This study was a single-arm single center prospective phase II clinical study. A total of 72 subjects who meet the criteria will receive neoadjuvant chemotherapy of nab-paclitaxel and S-1 prior to pancreatectomy. Response was reported according to the Response Evaluation Criteria in Solid Tumors guidelines (RECIST, version 1.1) .The primary endpoint is objective response rate. The secondary endpoints include R0/R1 resection rate, disease free survival, overall survival and safety.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Neoplasms | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nab paclitaxel and S-1 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- nab-paclitaxel and S-1
- description
- neoadjuvant chemotherapy with Nab-paclitaxel and S-1, repeat every 21 days for 2-4 cycles
- interventionNames
- Drug: Nab paclitaxel and S-1
Primary outcomes (1)
- measure
- Objective response rate
- timeFrame
- From date of first dose until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 24 months
- description
- Percentage of patients who achieve partial response (PR) or complete response(CR) based on Response Evaluation Criteria In Solid Tumors (RECIST1.1)
Secondary outcomes (3)
- measure
- R0/R1 resection rate
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Signed informed-consent form; 2. Treatment-naive PDAC with histological or cytological diagnosis; 3. Resectable pancreatic cancer stage II and partial stage III defined according to the National Comprehensive Cancer Network definitions; 4. Age≥18 years old and ≤70 years old; 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 6. BMI≥18.5 and NRS2002score\<3; 7. Expected survival over 3 months; 8. Spared organ function satisfying the following laboratory data:leucocyte≥3.0x109/L,neutrophils≥1.5x109/L, hemoglobin≥ 9g/dL, platelets ≥100x109/L, total bilirubin ≤ 1.5 ULN; AST and ALT≤ 2.5 ULN; serum creatinine≤1.5ULN; PT and INR≤ 2.5 ULN; Exclusion Criteria: 1. Severe Impaired organ functions; 2. Patients who had surgeries, chemotherapy or other treatments before inclusion; 3. Pregnant women or lactating women; 4. Ineligible by the discretion of the investigator.
References
Publications (0)
Data not yet available